INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of “Hold” by Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have received a consensus recommendation of “Hold” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $8.00.

A number of equities research analysts have recently issued reports on the company. Wall Street Zen cut INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Lucid Cap Mkts upgraded INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th.

Institutional Investors Weigh In On INmune Bio

Hedge funds have recently added to or reduced their stakes in the business. Intech Investment Management LLC bought a new position in INmune Bio during the second quarter worth $26,000. Cary Street Partners Financial LLC acquired a new position in shares of INmune Bio in the third quarter valued at $29,000. Independent Advisor Alliance acquired a new stake in shares of INmune Bio during the 3rd quarter worth about $30,000. Squarepoint Ops LLC acquired a new stake in shares of INmune Bio during the 3rd quarter worth about $30,000. Finally, Quadrature Capital Ltd bought a new stake in shares of INmune Bio during the 4th quarter worth about $26,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Stock Up 2.1%

Shares of INmune Bio stock opened at $1.44 on Friday. INmune Bio has a 12-month low of $1.09 and a 12-month high of $11.64. The stock has a market cap of $38.28 million, a P/E ratio of -0.86 and a beta of 1.04. The business’s 50 day moving average is $1.34 and its 200-day moving average is $1.51.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.